Type 2 DM: As monotherapy in patients inadequately controlled by diet & exercise for whom metformin is inappropriate because of contraindications or intolerance. As dual therapy in combination w/ metformin in patients w/ insufficient glycemic control despite maximal tolerated dose of monotherapy w/ metformin. As triple oral therapy in combination w/ metformin in patients w/ insufficient glycemic control despite dual oral therapy.
Not to be used in patients w/ active or history of heart failure & bladder cancer. Not indicated to patient w/ NYHA class III or IV cardiac status. Fluid retention may develop & risk of hypoglycemia. Patients w/ edema. Dose-related wt gain & resumption of ovulation may occur. Decreased Hb & hematocrit. Discontinue if any deterioration in cardiac status or jaundice occurs. Liver dysfunction.